Outcomes and Implications of Negative mpMRI in Prostate Cancer Detection

Overview

In a retrospective study of 216 men with negative multiparametric MRI (mpMRI) for prostate cancer (PCa), 20.7% of biopsied patients were diagnosed with PCa, but only 6.7% had clinically significant PCa (csPCa). Age was an independent predictor for undergoing biopsy, while PSA levels and PSA density were not predictive after negative mpMRI.

Background

Multiparametric MRI (mpMRI) has improved prostate cancer detection and is recommended prior to biopsy by EAU guidelines. However, the necessity of biopsy in patients with negative mpMRI but clinical suspicion remains controversial due to concerns about overdiagnosis and overtreatment. Additional prognostic factors such as PSA metrics have not been validated for guiding biopsy decisions in MRI-negative patients. This study evaluates outcomes after negative mpMRI to better understand the risk of undetected csPCa and inform biopsy decisions.

Data Highlights

Key Findings

• Out of 216 patients with negative mpMRI (PI-RADS ≤ 2), 75% underwent prostate biopsy.
• 20.7% of biopsied patients were diagnosed with prostate cancer, but only 6.7% had clinically significant disease (ISUP ≥ 2).
• Older age was independently associated with a lower likelihood of undergoing biopsy after negative mpMRI (OR 0.907, p = 0.001).
• PSA level, free PSA, and PSA density were not independent predictors for biopsy decision after negative mpMRI.
• Patients not undergoing biopsy were older, had lower PSA and PSA density, and more frequently received treatment for benign prostatic hyperplasia (BPH).
• Neither prior negative biopsy nor absence of PI-RADS lesions independently predicted biopsy performance after negative mpMRI.

Clinical Implications

Negative mpMRI significantly reduces but does not eliminate the risk of clinically significant prostate cancer, supporting cautious consideration before omitting biopsy. Age influences biopsy decisions more than PSA metrics in MRI-negative patients, suggesting that PSA-based parameters alone may be insufficient to guide biopsy. Clinicians should integrate patient age, clinical suspicion, and mpMRI findings when deciding on biopsy to avoid unnecessary procedures and overtreatment.

Conclusion

Negative mpMRI is associated with a low but not negligible rate of clinically significant prostate cancer. Age is a key factor influencing biopsy decisions, while PSA parameters lack predictive value in this setting, highlighting the need for improved risk stratification tools in MRI-negative patients.

References

1. EAU Guidelines 2022 -- Prostate Cancer Diagnosis and Management
2. Study Data 2018-2020 -- Outcomes after Negative mpMRI in Prostate Cancer